natgillin/translations-raw huggingface dataset:
Table eggs for human consumption
Tallene for regnskabsåret 2004 er blevet tilpasset, så de kan sammenholdes med tallene for regnskabsåret 2005.
This declaration is only required to be completed when the official health certificate is issued after departure of the consignment. If not required, the statement must be deleted.
To izjavo je treba izpolniti le, kadar se uradno zdravstveno spričevalo izda po odhodu pošiljke.
Reference to legislation includes all subsequent amendments. ‘
Sklicevanje na zakonodajo vključuje vse poznejše spremembe.
establishing a Committee on monetary, financial and balance of payments statistics
o ustanovitvi Odbora za monetarno, finančno in plačilno-bilančno statistiko
Council Decision 91/115/EEC of 25 February 1991 establishing a Committee on monetary, financial and balance of payments statistics [3] has been substantially amended [4].
Sklep Sveta 91/115/EGS z dne 25. februarja 1991 o ustanovitvi Odbora za monetarno, finančno in plačilno-bilančno statistiko [3] je bil bistveno spremenjen [4].
In the interests of clarity and rationality the said Decision should be codified.
Zaradi jasnosti in racionalnosti bi bilo treba navedeni sklep kodificirati.
There is a need to establish, as a section of the multiannual statistical programme of the Commission, a multiannual work programme in the field of monetary, financial and balance of payments statistics.
Na področju monetarne, finančne in plačilnobilančne statistike je potrebno oblikovati večletni program dela kot del večletnega statističnega programa Komisije.
By Decision 89/382/EEC, Euratom of 19 June 1989 establishing a Committee on the Statistical Programmes of the European Communities [5] the Council set up a Committee on the Statistical Programme of the European Communities, comprising representatives of the Member States' statistical institutes, to ensure close cooperation between Member States and the Commission whilst the statistical programme is established.
S Sklepom 89/382/EGS, Euratom z dne 19. junija 1989 o ustanovitvi Odbora za statistične programe Evropskih skupnosti [5] je Svet ustanovil Odbor za statistični program Evropskih skupnosti, ki je sestavljen iz predstavnikov statističnih uradov držav članic, da pri oblikovanju statističnega programa zagotovi tesno sodelovanje med državami članicami in Komisijo.
In Member States monetary and banking statistics are drawn up by central banks, and financial and balance of payments statistics are drawn up by various institutions, including central banks.
V državah članicah monetarno in bančno statistiko sestavljajo centralne banke, in finančne in plačilnobilančne statistike sestavljajo različne ustanove, vključno s centralnimi bankami.
It is necessary, in order to achieve close cooperation between Member States and the Commission in the fields of monetary, financial and balance of payments statistics that the Commission be assisted, in drawing up and implementing the multiannual work programme relating to such statistics, by a Committee composed of representatives of the principal national institutions concerned.
Za uresničevanje tesnega sodelovanja med državami članicami in Komisijo na področju monetarne, finančne in plačilnobilančne statistike je treba, da pri sestavljanju in izvajanju večletnega programa dela, ki se nanaša na takšno statistiko, Komisiji pomaga odbor, sestavljen iz predstavnikov zadevnih glavnih nacionalnih ustanov.
Having regard to the specific role played in the Member States by the aforementioned institutions, it is necessary to allow the committee to choose its chairman.
Ob upoštevanju posebne vloge, ki jo imajo zgoraj navedene ustanove v državah članicah, je treba odboru omogočiti, da izbere svojega predsednika.
There is, from the point of view of statistics, a close interdependence between the monetary, financial and balance of payments areas on the one hand, and certain other areas of economic statistics on the other hand.
Iz stališča statistike obstaja velika soodvisnost med monetarnimi, finančnimi in plačilnobilančnimi področji na eni strani in nekaterimi drugimi področji ekonomske statistike na drugi strani.
The increased demand from the Member States and Community institutions for improved statistical information requires the enhancement of cooperation between the users and producers of monetary, financial and balance of payments statistics,
Povečanje povpraševanja ustanov držav članic in Skupnosti po izboljšanih statističnih informacijah zahteva krepitev sodelovanja med uporabniki in proizvajalci monetarne, finančne in plačilnobilančne statistike –
A Committee on Monetary, Financial and Balance of Payments Statistics, hereinafter called ‘the Committee’, is hereby established.
Ustanovi se Odbor za monetarno, finančno in plačilno-bilančno statistiko, v nadaljevanju „odbor“.
The Committee shall assist the Commission in drawing up and implementing the multiannual programme of work relating to monetary, financial and balance of payments statistics.
Odbor pomaga Komisiji pri sestavljanju in izvajanju večletnega programa dela, ki se nanaša na monetarno, finančno in plačilnobilančno statistiko.
The Committee shall, in particular, have the task of expressing opinions on the development and coordination of the monetary, financial and balance of payments statistics required for the policies implemented by the Council, the Commission, and the various committees assisting them.
Naloga odbora je zlasti izražanje mnenj o razvoju in usklajevanju monetarne, finančne in plačilno-bilančne statistike, ki je potrebna za politike, ki jih izvajajo Svet, Komisija in različni odbori, ki jim pomagajo.
The Committee may be asked to express opinions on the links between monetary, financial and balance of payments statistics on the one hand, and certain other economic statistics on the other, in particular those on which national accounts are based.
Odbor se lahko zaprosi za mnenje o povezavah med monetarnimi, finančnimi in plačilno-bilančnimi področji na eni strani in nekaterimi drugimi področji ekonomske statistike na drugi strani, zlasti tistih, na katerih temeljijo nacionalni računi.
The work of this Committee will be coordinated with that of the Statistical Programme Committee.
Delo tega odbora bo usklajeno z delom Odbora za statistični program.
The Commission, on its own initiative, and, should the occasion arise, following a request from the Council or from the committees which assist them, shall consult the Committee on:
Komisija se na lastno pobudo, in če do tega pride, na zahtevo Sveta ali odborov, ki jim pomagajo, z odborom posvetuje o:
the establishment of multiannual Community programmes for monetary, financial and balance of payments statistics;
oblikovanju večletnega programa Skupnosti za monetarno, finančno in plačilno-bilančno statistiko;
the measures which the Commission intends to undertake to achieve the objectives referred to in the multiannual programmes for monetary, financial and balance of payments statistics and the resources and timetables involved;
ukrepih, ki jih Komisija namerava sprejeti za doseganje ciljev iz večletnega programa za monetarno, finančno in plačilno-bilančno statistiko in vključenih virih in časovnih razporedih;
any other question, in particular questions of methodology, arising from the establishment or implementation of the Statistical Programme in the relevant fields.
vseh drugih vprašanjih, zlasti vprašanjih metodologije, ki se pojavljajo pri oblikovanju ali izvajanju Statističnega programa na ustreznih področjih.
The Committee may express opinions on its own initiative on any questions relating to the establishment or the implementation of statistical programmes in the monetary, financial and balance of payments fields.
Odbor lahko na lastno pobudo izraža mnenja o vseh vprašanjih, ki se nanašajo na oblikovanje ali izvajanje statističnih programov na monetarnem, finančnem in plačilnobilančnem področju.
The Committee may express opinions on its own initiative on any questions relating to those statistics that are of common concern to the Commission and national statistical authorities, on the one hand, and the European Central Bank (ECB) and national central banks, on the other.
Na svojo lastno pobudo odbor lahko izrazi svoje mnenje o vsakem vprašanju v zvezi s temi statističnimi podatki, ki so skupnega pomena za Komisijo in državne statistične organe na eni strani ter Evropsko centralno banko (ECB) in nacionalne centralne banke na drugi.
In the execution of its tasks, the Committee shall give its views to all interested parties.
Pri izvajanju svojih nalog odbor poda svoje mnenje vsem zainteresiranim strankam.
The Committee shall be composed of one, two or three representatives per Member State, coming from the institutions principally concerned with financial, monetary and balance of payments statistics, up to three representatives of the Commission and up to three representatives of the ECB.
Odbor je sestavljen iz enega, dveh ali treh predstavnikov vsake države članice, prihajajočih iz ustanov, ki se ukvarjajo pretežno z monetarno, finančno in plačilnobilančno statistiko, ter največ treh predstavnikov Komisije in največ treh predstavnikov ECB.
In addition, one representative of the Economic and Financial Committee may attend the meetings of the Committee, as an observer.
Poleg teh se lahko en predstavnik Ekonomsko-finančnega odbora udeležuje sej kot opazovalec.
Each Member State, the Commission and the ECB shall have one vote each.
Vsaka država članica, Komisija in ECB imajo po en glas.
Representatives of other organisations, as well as any person able to contribute to discussions, may, on the decision of the Committee, participate in the Committee's meetings.
Predstavniki drugih organizacij, pa tudi vsaka oseba, ki lahko prispeva k razpravi, se lahko po odločitvi obora, udeleži njegovih sej.
The Committee shall elect its chairman according to the detailed rules laid down in its rules of procedure.
Odbor izvoli svojega predsednika na podlagi podrobnih pravil, določenih v njegovem poslovniku.
The Committee shall draw up its rules of procedure.
Odbor sprejme svoj poslovnik.
Decision 91/115/EEC is repealed.
Sklep 91/115/EGS se razveljavi.
References made to the repealed Decision shall be construed as being made to this Decision and should be read in accordance with the correlation table in Annex II.
Sklici na razveljavljeni Sklep se upoštevajo kot sklici na ta sklep in se berejo v skladu s primerjalno tabelo v Prilogi II.
OJ C 97 E, 22.4.2004, p. 68.
UL C 97 E, 22.4.2004, str. 68.
OJ C 10, 14.1.2004, p. 27.
UL C 10, 14.1.2004, str. 27.
Decision as amended by Decision 96/174/EC (OJ L 51, 1.3.1996, p. 48).
Sklep, kakor je bil spremenjen s Sklepom 96/174/ES (UL L 51, 1.3.1996, str. 48)
Repealed Decision and its amending Decision
Razveljavljeni sklep z njegovo spremembo
Council Decision 91/115/EEC
Sklep Sveta 91/115/EGS
(OJ L 59, 6.3.1991, p. 19)
(UL L 59, 6.3.1991, str. 19)
Council Decision 96/174/EC
Sklep Sveta 96/174/ES
(OJ L 51, 1.3.1996, p. 48)
(UL L 51, 1.3.1996, str. 48)
Decision 91/115/EEC
Sklep 91/115/EGS
Articles 1-3
Členi 1 do 3
relating to a proceeding under Article 82 of the EC Treaty and Article 54 of the EEA Agreement
v zvezi s postopkom na podlagi člena 82 Pogodbe ES in člena 54 Sporazuma EGP
(Case COMP/A.37.507/F3 — AstraZeneca) [1](notified under document number C(2005) 1757)
(Zadeva COMP/A.37.507/F3 – AstraZeneca) [1](notificirano pod dokumentarno številko C(2005) 1757)
(Only the English and Swedish texts are authentic)
(Besedilo v angleškem in švedskem jeziku je edino verodostojno)
On 15 June 2005, the Commission adopted a decision relating to a proceeding under Article 82 of the EC Treaty and Article 54 of the EEA Agreement.
Komisija je 15. junija 2005 sprejela odločbo v zvezi s postopkom na podlagi člena 82 Pogodbe ES in člena 54 Sporazuma EGP.
In accordance with the provisions of Article 30 of Regulation (EC) No 1/2003 [2], the Commission herewith publishes the names of the parties and the main content of the decision, including any penalties imposed, having regard to the legitimate interest of undertakings in the protection of their business secrets.
Komisija v skladu z določbami člena 30 Uredbe (ES) št. 1/2003 [2] objavlja imena strank in glavno vsebino Odločbe, vključno z vsemi naloženimi sankcijami, ob upoštevanju pravnega interesa podjetij do varovanja njihovih poslovnih skrivnosti.
A non-confidential version of the full text of the decision in the authentic languages of the case (English and Swedish) can be found at DG COMP’s website at http://europa.eu.int/comm/competition/index_en.html1.
Različica celotnega besedila odločbe, ki ni zaupna, je na voljo v verodostojnih jezikih zadeve (angleščini in švedščini) na spletni strani GD COMP: http://europa.eu.int/comm/competition/index_en.html1.
SUMMARY OF THE INFRINGEMENTS
POVZETEK KRŠITEV
Addresses and the nature of the infringements
Naslovniki in narava kršitev
The decision is addressed to the Swedish company AstraZeneca AB and the UK company AstraZeneca Plc (hereinafter ‘AZ’) due to their infringements of Article 82 of the EC Treaty and Article 54 of the EEA Agreement.
Odločba je naslovljena na švedsko podjetje AstraZeneca AB in podjetje iz Združenega kraljestva AstraZeneca Plc (v nadaljnjem besedilu „AZ“) zaradi njunih kršitev člena 82 Pogodbe ES in člena 54 Sporazuma EGP.
The infringements concern abuses by AZ of government procedures in seven EEA Contracting States aimed at excluding generic firms and — in the context of the second infringement — parallel traders from competing against AZ’s pharmaceutical product Losec.
Kršitve zadevajo zlorabe uradnih postopkov s strani podjetja AZ v sedmih državah pogodbenicah EGP s ciljem izključitve generičnih podjetij in v okviru druge kršitve izključitve vzporednih trgovcev iz konkurence za farmacevtski izdelek Losec podjetja AZ.
The first abuse involved misuses of a Council Regulation [3] (hereinafter ‘SPC Regulation’) under which the basic patent protection for pharmaceutical products can be extended.
Prva kršitev vključuje zlorabe Uredbe Sveta [3] (v nadaljnjem besedilu „Uredba DVC“), v skladu s katero se osnovno patentno varstvo za farmacevtske izdelke lahko podaljša.
The second abuse concerned misuses of procedures relating to the authorisation of marketing of pharmaceutical products.
Pri drugi kršitvi gre za zlorabo postopkov za dovoljenje za trženje farmacevtskih izdelkov.
Relevant market and dominance
Upoštevni trg in prevladujoči položaj
The relevant market comprises national markets for so-called proton pump inhibitors (hereinafter ‘PPIs’) sold on prescription which are used for gastro-intestinal acid related diseases (such as ulcers).
Upoštevni trg zajema nacionalne trge za tako imenovane inhibitorje protonske črpalke (v nadaljnjem besedilu „IPČ“), ki se prodajajo na recept in se uporabljajo za zdravljenje gastrointestinalnih bolezni, povezanih z želodčno kislino (kot je ulkus).
AZ’s Losec was the first PPI.
Izdelek Losec podjetja AZ je bil prvi IPČ.
More specifically, the decision finds that a PPI market can be established at least from 1993 in Belgium, Denmark, Germany, the Netherlands, Sweden and the UK and from 1992 in Norway.
Bolj podrobno je v Odločbi ugotovljeno, da se trg IPČ lahko ugotovi vsaj od leta 1993 v Belgiji, na Danskem, v Nemčiji, na Nizozemskem, Švedskem in v Združenem kraljestvu ter od leta 1992 na Norveškem.
The decision finds that AZ held a dominant position on the PPI market in Belgium, the Netherlands, Sweden (from 1993 until the end of 2000), Norway (from 1994 until the end of 2000), Denmark and the UK (from 1993 until the end of 1999) and Germany (from 1993 until the end of 1997).
V Odločbi je ugotovljeno, da je podjetje AZ imelo prevladujoč položaj na trgu IPČ v Belgiji, na Nizozemskem, Švedskem (od leta 1993 do konca leta 2000), Norveškem (od leta 1994 do konca leta 2000), Danskem in v Združenem kraljestvu (od leta 1993 do konca leta 1999) ter v Nemčiji (od leta 1993 do konca leta 1997).
The first infringement
Prva kršitev
The first infringement of Article 82 of the EC Treaty and Article 54 of the EEA Agreement constitutes a single and continuous abuse and consists of a pattern of misleading representations made by AZ before patent offices in Belgium, Denmark, Germany, the Netherlands, Norway and the UK and before national courts in Germany and Norway.
Prva kršitev člena 82 Pogodbe ES in člena 54 Sporazuma EGP pomeni eno samo in trajno zlorabo in je sestavljena iz zavajajočih razlag pri patentnih uradih v Belgiji, na Danskem, Nizozemskem, Norveškem in v Združenem kraljestvu ter na nacionalnih sodiščih v Nemčiji in na Norveškem.
The misleading information was initially provided by AZ in the context of its applications to several patent offices in June 1993 and December 1994 within the EEA for extra protection for omeprazole (the active substance in AZ’s product Losec) in the form of so-called supplementary protection certificates.
AZ je na začetku podala zavajajoče informacije v vlogah, ki jih je junija 1993 in decembra 1994 poslala več patentnim uradom znotraj EGP, za dodatno varovanje za omeprazol (zdravilna učinkovina v izdelku Losec podjetja AZ) v obliki tako imenovanega dodatnega varstvenega certifikata.
The second infringement
Druga kršitev
The second infringement of Article 82 of the EC Treaty and Article 54 of the EEA Agreement constitutes a single and continuous abuse and consists of AZ’s requests for the surrender of its market authorisations for Losec capsules in Denmark, Norway and Sweden combined with its withdrawal from the market of Losec capsules and launch of Losec MUPS tablets in those three countries.
Druga kršitev člena 82 Pogodbe ES in člena 54 Sporazuma EGP pomeni eno samo in trajno zlorabo in je sestavljena iz zahtev AZ za odjavo svojih dovoljenj za promet s kapsulami Losec na Danskem, Norveškem in Švedskem, združeno z umikom kapsul Losec s trga in lansiranjem tablet Losec MUPS v navedenih treh državah.
The decision finds that the nature of the infringements and their geographic scope are such that the infringements must be qualified as serious.
V Odločbi je ugotovljeno, da je narava kršitev in njihov geografski obseg takšen, da je treba kršitve opredeliti kot hude.
The qualification of the infringements as serious takes into account that the abuses in this case present some specific and novel features regarding the means used and cannot be said to have been clear-cut ones.
Opredelitev kršitev za hude upošteva, da zlorabe v tem primeru predstavljajo nekaj posebnih in novih značilnosti glede uporabljenih sredstev in zato ni mogoče reči, da gre za jasne kršitve.
The decision also takes account of the fact that AstraZeneca Plc is only jointly and severally liable for the infringements with effect from the merger between Astra AB (currently AstraZeneca AB) and Zeneca Plc on 6 April 1999.
V Odločbi se tudi upošteva dejstvo, da je AstraZeneca Plc le solidarno odgovorna za kršitve od združitve med Astra AB (zdaj AstraZeneca AB) in Zeneca Plc od 6. aprila 1999 naprej.
Opinion of the Advisory Committee (OJ C 291, 30.11.2006).
Mnenje Svetovalnega odbora (UL C 291, 30.11.2006).
SPCs are granted pursuant to Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products (OJ L 182, 2.7.1992, p. 1).
DVC se dodelijo na podlagi Uredbe Sveta (EGS) št. 1768/92 z dne 18. junija 1992 o uvedbi dodatnega varstvenega certifikata za zdravila (UL L 182, 2.7.1992, str. 1).
The fine of EUR 60000000 is divided as follows.
Globa v znesku 60000000 EUR se razdeli, kot sledi.
AstraZeneca AB and AstraZeneca are jointly and severally liable for EUR 46000000 whereas AstraZeneca AB is solely liable for EUR 14000000.
AstraZeneca AB in AstraZeneca sta solidarno odgovorni za 46000000 EUR, AstraZeneca AB pa je izključno odgovorna za 14000000 EUR.
(notified under document number C(2006) 5607)
(notificirano pod dokumentarno številko C(2006) 5607)
Commission Decision 2005/393/EC of 23 May 2005 on protection and surveillance zones in relation to bluetongue and conditions applying to movements from or through these zones [2] provides for the demarcation of the global geographic areas where protection and surveillance zones (the restricted zones) are to be established by the Member States in relation to bluetongue.
Odločba Komisije 2005/393/ES z dne 23. maja 2005 o okuženih in ogroženih območjih zaradi bolezni modrikastega jezika in o pogojih, ki veljajo za premike s teh območij ali prek teh območij [2], določa razmejitev globalnih geografskih območij, kjer morajo države članice določiti okužena in ogrožena območja („območja z omejitvami“) v zvezi z boleznijo modrikastega jezika.
On 3 November 2006 Portugal informed the Commission that serotype 4 virus has been detected as circulating in a number of peripheral areas of restricted zone E. Consequently that zone should be extended, taking into account the data available on the ecology of the vector and the current meteorological situation.
Portugalska je 3. novembra 2006 obvestila Komisijo, da so na številnih obrobnih delih območja z omejitvami E odkrili širjenje virusa serotip 4. Zato je treba ob upoštevanju razpoložljivih podatkov o ekologiji vektorja in trenutnih vremenskih razmer navedeno območje razširiti.
Following the notification of outbreaks of bluetongue in mid-August and early September 2006 by Belgium, Germany, France and the Netherlands, the Commission has amended several times Decision 2005/393/EC as regards the demarcation of the restricted zone concerned.
Komisija je po obvestilu Belgije, Nemčije, Francije in Nizozemske o izbruhu bolezni modrikastega jezika sredi avgusta in na začetku septembra 2006 večkrat spremenila Odločbo 2006/393/ES v zvezi z razmejitvijo zadevnih območij z omejitvami.
On 6 November 2006 Germany informed the Commission of new outbreaks of bluetongue in North-Rhine-Westphalia, Rhineland-Palatinate and Lower Saxony.
Nemčija je 6. novembra 2006 Komisijo obvestila o novih izbruhih bolezni modrikastega jezika v Severnem Porenju – Vestfaliji, Porenju – Pfalz in Spodnji Saški.
In view of those findings, it is appropriate to amend the demarcation of the restricted zone in Germany and France.
Glede na navedene ugotovitve je primerno spremeniti razmejitev omejenega območja v Nemčiji in Franciji.
On 6 November 2006 Italy also informed the Commission that serotype 1 virus has been detected as circulating for the first time in Cagliari province in the Sardegna region already located in the restricted zone C. Consequently, in view of those new findings, it is appropriate to insert a new restricted zone including the affected area.
Prav tako je Italija 6. novembra 2006 obvestila Komisijo, da so v pokrajini Cagliari v regiji Sardinija, ki se že nahaja na območju z omejitvami C, prvič odkrili širjenje virusa serotip 1. Glede na navedene nove ugotovitve je zato primerno, da se vstavi nova območja z omejitvami, ki vključujejo prizadeta območja.
Decision as last amended by Decision 2006/761/EC (OJ L 311, 10.11.2006, p. 51).
Odločba, kakor je bila spremenjena z Odločbo 2006/761/ES (UL L 311, 10.11.2006, str. 51).
The list of restricted zones in Zone C (serotypes 2 and 4 and to a lesser extent 16) which relates to Italy is replaced by the following:
Seznam območij z omejitvami v območju C (serotipi 2 in 4 ter v manjši meri 16) za Italijo se nadomesti z naslednjim:
‘Italy
„Italija:
The list of restricted zones in Zone E (serotype 4) which relates to Portugal is replaced by the following:
Seznam območij z omejitvami v območju E (serotip 4) za Portugalsko se nadomesti z naslednjim:
‘Portugal
„Portugalska:
Regional Direction of Agriculture of Ribatejo e Oeste: concelhos of Almada, Barreiro, Moita, Seixal, Sesimbra, Montijo, Coruche, Setúbal, Palmela, Alcochete, Benavente, Salvaterra de Magos, Almeirim, Alpiarça, Chamusca, Constância, Abrantes, Sardoal, Alenquer, Golegã, Cartaxo, Azambuja, Vila Franca de Xira, Vila Nova da Barquinha e Santarém.
regionalna kmetijska urada Ribatejo in Oeste: concelhos Almada, Barreiro, Moita, Seixal, Sesimbra, Montijo, Coruche, Setúbal, Palmela, Alcochete, Benavente, Salvaterra de Magos, Almeirim, Alpiarça, Chamusca, Constância, Abrantes, Sardoal, Alenquer, Golegã, Cartaxo, Azambuja, Vila Franca de Xira, Vila Nova da Barquinha in Santarém